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Abstract: Mephedrone, which is one of the most popular synthetic cathinones, has one chiral centre
and thus exists as two enantiomers: R-(+)-mephedrone and S-(−)-mephedrone. There are some
preliminary data suggesting that the enantiomers of mephedrone may display enantioselective phar-
macokinetics and exhibit different neurological effects. In this study, enantiomers of mephedrone
were resolved via chromatographic chiral recognition and the absolute configuration was unambigu-
ously determined by a combination of elution order and chiroptical analysis (i.e., circular dichroism).
A chiral liquid chromatography tandem mass spectrometry method was fully validated and was
applied to the analysis of whole blood samples collected from a controlled intranasal administra-
tion of racemic mephedrone hydrochloride to healthy male volunteers. Both enantiomers showed
similar kinetics, however, R-(+)-mephedrone had a greater mean Cmax of 48.5 ± 11.9 ng/mL and a
longer mean half-life of 1.92 ± 0.27 h compared with 44.6 ± 11.8 ng/mL and 1.63 ± 0.23 h for S-(−)-
mephedrone, respectively. Moreover, R-(+)-mephedrone had a lower mean clearance and roughly
1.3 times greater mean area under the curve than S-(−)-mephedrone. Significant changes in the
enantiomeric ratio over time were observed, which suggest that the analytes exhibit enantioselective
pharmacokinetics. Even though the clinical significance of this finding is not yet fully understood,
the study confirms that the chiral nature, and consequently the enantiomeric purity of mephedrone,
can be a crucial consideration when interpreting toxicological results.
Keywords: mephedrone; enantiomers; whole blood; pharmacokinetics; intranasal administration
1. Introduction
Mephedrone (4-methylmethcathinone) is a popular synthetic cathinone which is
structurally and chemically similar to other stimulant drugs, such as amphetamine [1].
With a single chiral centre at the α-carbon, mephedrone exists as two enantiomers: R-(+)-
mephedrone (R-MEPH) and S-(−)-mephedrone (S-MEPH) [2], as shown in Figure 1.
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Figure 1. Chemical structure of mephedrone enantiomers. 
Even though recreational use of mephedrone in Europe began in 2009, its synthesis 
was first described in 1929 [3]. The main synthetic route involves α-bromination of 
4-methylpropiophenone and a subsequent reaction with methylamine hydrochloride and 
triethylamine. The resulting mixture is treated with gaseous or aqueous hydrochloric acid 
and is recrystallised to yield mephedrone hydrochloride [4]. This method produces a ra-
cemic mixture but a stereoselective synthesis via Friedel–Crafts acylation can also be per-
formed [5]. Even though stereoselective synthesis is possible, it is thought that “street 
mephedrone” has been primarily sold as a racemic mixture [6], which is most likely at-
tributed to the simplicity of the synthesis and the availability of the precursors. 
Enantiomers usually differ in their biochemical activity which may result in one en-
antiomer being biologically active while the other may be inactive or may even produce 
adverse effects [7]. To our knowledge, there are no published reports available on phar-
macokinetics of mephedrone enantiomers in humans, but preliminary data derived from 
both in vitro experiments, animal studies and analysis of human urine suggest that 
mephedrone enantiomers may have a different metabolic pathway and exhibit different 
neurological effects [2,8–10]. Castrignanò et al. found that R-MEPH was the predominant 
analyte in in vitro experiments performed in human liver microsomes and in pooled hu-
man urine collected from music festivals [2]. By contrast, a different study that investi-
gated the presence of 56 biomarkers (including mephedrone) in wastewater found sam-
ples to be enriched with S-MEPH [9]. A study in rats has shown that R-MEPH results in 
more stimulant-like effects than S-MEPH due to its higher selectivity for dopaminergic 
system [8]. Moreover, the phase 1 metabolites of mephedrone possess bioactive proper-
ties, with the stereoisomers inhibiting dopamine, norepinephrine and serotonin transport-
mediated uptake. Of note is that the S-enantiomers of nor-mephedrone and 4-hydroxy-
tolyl-mephedrone have been reported to be several times more potent as inhibitors of ser-
otonin mediated uptake than the corresponding R-enantiomers [10]. All in all, assessing 
the degree of asymmetry in the abundance of the enantiomers of mephedrone and its me-
tabolites in biological samples should hopefully add insight into the pharmacodynamics 
of the drug. 
In a recently published study describing detection of racemic mephedrone in human 
whole blood and plasma, mephedrone was detected for 6 h post administration and 
showed rapid absorption and elimination [11]. Herein, we report the first in-depth inves-
tigation of pharmacokinetic profiles of mephedrone enantiomers derived from whole 
blood analysis following a controlled intranasal administration of 100 mg of pure racemic 
mephedrone hydrochloride to healthy human volunteers. 
2. Results 
2.1. Method Validation 
The results of method validation are presented in Supplementary Materials. Briefly, 
intra- and inter-day precision were within ±15% of the true value (Table S2 in Supplemen-
tary Materials). Mean linearity of R2 > 0.999 was achieved for both enantiomers in all three 
validation runs (Figure S1 and Table S1 in Supplementary Materials). Matrix effect ranged 
Figure 1. Che ical structure of ephe r e e a ti rs.
Even though recreational use of ephedrone in Europe began in 2009, its synthesis
as first described in 1929 [3]. The main synthetic route involves α-bromination of 4-
methylpropiophenone and a subsequent reaction with ethyla ine hydrochloride and
triethylamine. The resulting mixture is treated with gaseous or aqueous hydrochloric
acid and is recrystallised to yield mephedrone hydrochloride [4]. This method produces
a racemic mixture but a stereoselective synthesis via Friedel–Crafts acylation can also
be performed [5]. Even though stereoselective synthesis is possible, it is thought that
“street mephedrone” has been primarily sold as a racemic mixture [6], which is most likely
attributed to the simplicity of the synthesis and the availability of the precursors.
Enantiomers usually differ in their biochemical activity which may result in one enan-
tiomer being biologically active while the other may be inactive or may even produce
adverse effects [7]. To our knowledge, there are no published reports available on pharma-
cokinetics of mephedrone enantiomers in humans, but preliminary data derived from both
in vitro experiments, animal studies and analysis of human urine suggest that mephedrone
enantiomers may have a different metabolic pathway and exhibit different neurological
effects [2,8–10]. Castrignanò et al. found that R-MEPH was the predominant analyte in
in vitro experiments performed in human liver microsomes and in pooled human urine col-
lected from music festivals [2]. By contrast, a different study that investigated the presence
of 56 biomarkers (including mephedrone) in wastewater found samples to be enriched
with S-MEPH [9]. A study in rats has shown that R-MEPH results in more stimulant-like
effects than S-MEPH due to its higher selectivity for dopaminergic system [8]. Moreover,
the phase 1 metabolites of mephedrone possess bioactive properties, with the stereoisomers
inhibiting dopamine, norepinephrine and serotonin transport-mediated uptake. Of note
is that the S-enantiomers of nor-mephedrone and 4-hydroxytolyl-mephedrone have been
reported to be several times more potent as inhibitors of serotonin mediated uptake than
the corresponding R-enantiomers [10]. All in all, assessing the degree of asymmetry in the
abundance of the enantiomers of mephedrone and its metabolites in biological samples
should hopefully add insight into the pharmacodynamics of the drug.
In a recently published study describing detection of racemic mephedrone in human
whole blood and plasma, mephedrone was detected for 6 h post administration and showed
rapid absorption and elimination [11]. Herein, we report the first in-depth investigation of
pharmacokinetic profiles of mephedrone enantiomers derived from whole blood analysis
following a controlled i tranasal administration of 100 mg of pure racemic mep edrone
hydr chloride to healthy human volunteers.
2. Results
2.1. Method Validation
The results of method validation are presented in Supplementary Materials. Briefly,
intra- and inter-day precision were within ±15% of the true value (Table S2 in Supple-
mentary Materials). Mean linearity of R2 > 0.999 was achieved for both enantiomers in all
three validation runs (Figure S1 and Table S1 in Supplementary Materials). Matrix effect
ranged from 97.5 ± 5.2% to 102 ± 7.7% for both enantiomers (Table S3 in Supplementary
Materials). Carryover was not observed.
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2.2. Determination of the Elution Order
Alongside collected fractions, 1 mg/mL solutions of pure methcathinone enantiomers
were analysed by circular dichroism (CD) spectroscopy. Figure 2 shows the CD spectrum
of S-(−)-methcathinone and R-(+)-methcathinone (Figure 2A, mirror-image CD profiles)
and the second eluting peak of (±)-mephedrone samples (see Figures S3 and S4 in Sup-
plementary Materials for the chiral chromatographic separation). The CD spectrum of
the second eluting peak produces a broad positive Cotton effect between 220 and 270 nm
(Figure 2B), fully matching the positive peak recorded for S-(−)-methcathinone. Therefore,
(S)-absolute configuration can be confidently assigned to the second eluting peak collected
from (±)-mephedrone samples. Indirectly, this result also confirms that the first eluting
peak of (±)-mephedrone is the R-(+)-mephedrone, a conclusion based on the structural
homology between mephedrone and methcathinone.
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Figure 2. Circular dichroism profiles of (A) pure S-(−)-methcathinone and R-(+)-methcathinone and (B) racemic mephedrone
and t e second eluting peak from (±)-mephedrone samples (i.e., S-(−)-mephedrone).
2.3. Concentrations of Mephedrone Enantiomers in Whole Blood
In order to highlight individual changes in analyte concentration, Figure 3 shows
concentration profiles of S-MEPH and R-MEPH in each participant (M2–M6) up to 6 h post
administration. R-MEPH and S-MEPH were detected in whole blood between 5 and
360 min, but R-MEPH reached higher concentrations between 20 and 360 min in all
participants. Analytes were not detectable on Day 2 or Day 3.
2.4. Enantiomeric Ratio (ER)
ER, used to show the proportion of enantiomers in a mixture [12], was determined by
the relative percentages of the peak area ratios according to Equation (1) [13].
Equation (1). Equation for calculating enantiomeric ratio.
Enantiomeric ratio =
peak area ratio o f R − MEPH
peak area ratio o f S − MEPH (1)
ER is expected to be 1.0 if both enantiomers re present in a matrix at 1:1 ratio
(i.e., racemic mixture). ER calculate for each participant at each timepoint between 5
and 360 min is presented in Figure 4. According to the one sample t-test, statistically
significant changes from the expected value of 1.0 start to emerge at 45 min (mean
ER ± SD = 1.09 ± 0.04, p-value: 0.005) and continue until 360 min (mean ER ± SD =
1.51 ± 0.25, p-value: 0.011). Calibration standards and quality control samples had mean
ER ± SD of 0.992 ± 0.056 across all runs.
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2.5. Pharmacokinetic Analysis
Whole blood drug concentrations were fitted with a single-dose first-order elimination
phase model and calculated pharmacokinetic parameters are summarised in Table 1.
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Table 1. Pharmacokinetic data from the analysis of R-(+)-mephedrone (R-MEPH) and S-(−)-mephedrone (S-MEPH) in whole blood
samples from five male participants (M2–M6).
R-MEPH
Cmax Tmax kel t1/2 AUC CL Vd
(ng/mL) (min) (min−1) (h) (ng mL−1 h) (mL min−1 kg−1) (L kg−1)
M2 41.1 60 0.006 1.87 192 114 18.5
M3 42.5 45 0.005 2.3 209 122 24.4
M4 38 45 0.006 2 179 157 27.2
M5 54.2 30 0.006 1.89 201 100 16.5
M6 66.7 45 0.007 1.56 219 137 18.6
Mean ± SD 48.5 ±11.9 45 ± 11 0.006 ± 0.001 1.92 ± 0.27 200 ± 16 126 ± 22 21.0 ± 4.5
S-MEPH
Cmax Tmax kel t1/2 AUC CL Vd
(ng/mL) (min) (min−1) (h) (ng mL−1 h) (mL min−1 kg−1) (L kg−1)
M2 36.8 45 0.007 1.69 150 146 21.4
M3 37.9 45 0.006 2.01 168 153 26.6
M4 35.7 45 0.007 1.57 130 216 29.4
M5 49.7 30 0.008 1.45 136 148 18.6
M6 63.2 30 0.008 1.44 191 158 19.7
Mean ± SD 44.6 ±11.8 39 ± 8 0.007 ± 0.001 1.63 ± 0.23 155 ± 25 164 ± 29 23.1 ± 4.6
Both enantiomers showed similar kinetics but S-MEPH peaked earlier at 39 ± 8 min
and had shorter t1/2 of 1.63 ± 0.23 h compared to 45 ± 11 min and 1.92 ± 0.27 h for
R-MEPH, respectively. Differences in the area under the curve (AUC) and clearance (CL)
were also observed. R-MEPH resulted in roughly 1.3 times greater mean AUC compared
to S-MEPH and had lower mean clearance of 126 ± 22 mL min−1 kg−1 compared with
164 ± 29 mL min−1 kg−1 for the other enantiomer. Mean Vd was similar for R-MEPH
(21.0 ± 4.5 L kg−1) and S-MEPH (23.1 ± 4.6 L kg−1).
Paired t-test was performed to check if the pharmacokinetic parameters obtained for
R-MEPH and S-MEPH were significantly different. At 95% confidence level, Cmax, kel, t1/2,
AUC, CL and Vd were all statistically different, with the two-tailed p-value of 0.001, 0.004,
0.011, 0.002, 0.005, 0.002, respectively. The only parameter which did not show statistically
significant difference was Tmax (p-value of 0.178).
3. Discussion
The whole blood concentrations of R-MEPH reached a higher Cmax, had a greater
AUC and a longer t1/2 than S-MEPH in each of the participants. These results are in
agreement with previous research that found R-MEPH to be a predominant analyte in
pooled human urine samples and in in vitro experiments performed in human liver micro-
somes [9]. In the pharmacodynamic context, a study in rats has shown that R-MEPH rather
than S-MEPH results in more stimulant-like effects due to its 50-fold greater selectivity for
dopaminergic system [8]. R-MEPH was also found to be responsible for increased intracra-
nial self-stimulation, demonstrating greater abuse-related effects [8]. “Street mephedrone”
is thought to be sold as a racemic mixture, which has been primarily attributed to the
affordability and availability of the precursors [6]. Should the starting material become
unavailable, expensive or subject to strict international control, an alternative synthetic
route (perhaps enantiomerically specific) could be employed. If the resulting synthetic
product contains enantiomeric excess of R-MEPH, mephedrone users may be at risk of
greater toxicity.
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Recently published [11] mean racemic mephedrone concentrations in whole blood
were approximately two times higher than the mean concentrations of each individual
enantiomer. R-MEPH had more comparable pharmacokinetic parameters to those obtained
for racemic mephedrone in whole blood. Both peaked at approximately 50 min, had the
same kel of 0.006 ± 0.001 min−1 and nearly identical t1/2 of 2.12 ± 0.33 h for the racemic
mephedrone and 1.92 ± 0.27 h for R-MEPH. Cmax of 101 ± 45.4 ng/mL was observed
for racemic mephedrone, which was 2.26 times greater than the Cmax of S-MEPH and
2.08 times greater than the Cmax of R-MEPH.
Changes in the ER over time showed whole blood samples collected between 45 and
360 min to have a statistically different ER from the value of 1.0. Differences in concentra-
tions of S-MEPH and R-MEPH may be a result of pharmacokinetic processes occurring at
different rates during drug absorption, distribution, metabolism or excretion [14]. Some
drugs can be chemically or biochemically inverted in vivo in a unidirectional or bidirec-
tional manner [15]. Moreover, polymorphic drug metabolism, gender, age, disease state and
medications could all affect concentrations of enantiomers in whole blood, although given
the design of this study, polymorphic drug metabolism is likely to play the most significant
role. Hepatic cytochrome P450 2D6 (CYP2D6), responsible for mephedrone metabolism,
is subject to genetic polymorphism which causes variations in CYP2D6 enzymatic activ-
ity [16]. Participants in our study were not genotyped for CYP2D6 polymorphism but it
has been demonstrated that significantly altered mephedrone plasma concentrations can
be a result of CYP2D6 activity, with those who have no or low CYP2D6 functionality being
at greater risk of acute toxicity [17].
Even though chiral analysis is considered important and sometimes mandatory for
accurate interpretation of analytical findings [18], it is yet to be widely adopted as part
of routine procedures in clinical and forensic toxicology. In this context, it may be worth
following-up routine analysis of blood samples where mephedrone has been detected with
chiral analysis. A small number of case studies could be initially performed to understand
the usefulness of this additional information, in particular with reference to R-MEPH.
4. Materials and Methods
4.1. Reagents
Racemic mephedrone hydrochloride, racemic mephedrone-d3 hydrochloride (MEPH-
d3), S-(−)-methcathinone and R-(+)-methcathinone were purchased as certified reference
materials from Sigma-Aldrich (Dorset, UK). Racemic mephedrone hydrochloride in powder
form used for the human administration was purchased from Chiron (Trondheim, Norway).
The chemical structure, purity and racemic nature of the powder was confirmed by mass
spectrometry, circular dichroism (CD) spectroscopy and nuclear magnetic resonance.
All solvents were HPLC grade unless stated otherwise. Methanol (MeOH; HPLC grade
and Optima LC/MS grade), acetonitrile (ACN), isopropyl alcohol (IPA), dichloromethane
(DCM), sodium phosphate monobase, sodium phosphate diabase, formic acid, acetic
acid and ammonium hydroxide (0.88 S.G., 35%) were purchased from Fisher Scientific
(Loughborough, UK). Diethylamine (DEA) and ethanol (EtOH; LiChrosolv grade) were
purchased from Sigma-Aldrich (Dorset, UK). Ultrapure water (18 MΩcm) was prepared on
an ELGA Purelab Maxima HPLC water purification system (High Wycombe, UK). Xtrackt®
DAU High Flow (150 mg, 3 mL) cartridges were purchased from Chromatography Direct
(Runcorn, UK).
4.2. Blank Matrix
Drug-free whole blood was collected by trained phlebotomists into 5 mL Vacutainers®
(BD, Worthing, UK) containing 12.5 mg of sodium fluoride and 10 mg of potassium oxalate
(NaF/KOx).
Ethical approval for the collection of drug-free matrix was granted by the Research
Ethics Committee at King’s College London (HR 16/17 4237).
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4.3. Volunteer Administration Study and Sample Collection
All subjects gave their informed consent for inclusion before they participated in the
study. The study was conducted in accordance with the Declaration of Helsinki, and the
protocol was approved by the Riverside National Research Ethics Service (16/LO/1342).
Details of the administration study have been recently published [11]. Briefly, participants
enrolled into the study were occasional users of mephedrone or other stimulant drugs, but
were drug-free 1 week before the mephedrone administration, which was verified by urine
analysis (performed using a validated ultra-high-performance liquid chromatography–
high-resolution mass spectrometry method). Six healthy male volunteers nasally insufflated
100 mg of mephedrone hydrochloride supplied as a racemic mixture (purity: 96.3 ± 0.5%).
Whole blood (5 mL) was then collected into Vacutainers® containing NaF/KOx preservative
at 0 min (before administration on Day 1), 5 min, 10 min, 15 min, 20 min, 30 min, 45 min,
60 min, 75 min, 90 min, 105 min, 2 h, 2.5 h, 3 h, 5 h, 6 h, Day 2 and Day 3. Samples were
stored at +4 ◦C until analysis.
Whole blood samples were collected from six participants but for the purpose of this
study, samples from five participants (referred to here as M2–M6) were analysed. Whole
blood samples from participant M1 were discarded due to stability concerns [19] as they
had been collected five months before the chiral analysis commenced.
4.4. Working Solutions
Working solutions, used for the preparation of the calibration curve, contained
mephedrone only and were made in MeOH:water (50:50 v/v) at 160, 200, 400, 700, 1000,
2000, 4000 ng/mL. Working solution used for the preparation of the quality control (QC)
samples at low (Low), medium (Med) and high (High) levels were also made in the same
solvent at 200, 800, 3000 ng/mL, respectively. Internal standard (IS) solution, used for
quantification of analytes in the samples, contained racemic MEPH-d3 at 50 ng/mL in
MeOH:water (50:50 v/v).
4.5. Calibration Standards and Quality Control Samples
Matrix-matched calibration standards containing racemic mephedrone at 8, 10, 20,
35, 50, 100, 200 ng/mL were prepared by the addition of an appropriate volume of the
working solution to whole blood. QC Low at 10 ng/mL, QC Med at 40 ng/mL and QC
High at 150 ng/mL were prepared in the same way. As these racemic calibration standards
and QCs were separated into two enantiomers (i.e., two chromatographic peaks), half of
their concentration was used for plotting calibration curves and assessing the accuracy
of the QCs. Calibration curves were constructed by plotting concentration against peak
area ratio (i.e., peak area of each enantiomer divided by the peak area of the corresponding
enantiomer of the IS).
Calibration standards and QCs were prepared fresh on the day of sample analysis.
4.6. Sample Preparation
Sample extraction has been described before [19]. Briefly, 100 µL of whole blood was
taken through solid phase extraction using mixed-mode cartridges. Samples were eluted
with 4 × 1 mL of DCM:IPA:ammonium hydroxide (78:20:2 v/v/v) and dried under nitrogen
at 50 ◦C. Samples were then reconstituted with 100 µL of 0.1% DEA in EtOH:MeOH
(20:80 v/v).
4.7. Instrumentation
Sample analysis was performed by liquid chromatography–tandem mass spectrome-
try using a Xevo TQ-S triple quadrupole mass spectrometer (MS; Waters, Manchester, UK)
coupled to an Acquity ultra performance liquid chromatograph system (Waters, Manch-
ester, UK). Optimised MS conditions have been published elsewhere [19].
Mephedrone and MEPH-d3 were monitored using selected reaction monitoring (SRM)
as detailed in Table 2. Chromatographic separation was performed on a 150 mm × 3 mm,
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3 µm CHIRALPAK® AD-3 column (Illkirch, France) held at room temperature. The flow
rate was 0.1 mL/min with 0.1% DEA in EtOH:MeOH (20:80 v/v) as mobile phase used in
an isocratic mode. The total run time was 10 min.
Table 2. The retention time, selected reaction monitoring (SRM) transitions and collision energy for S-MEPH and R-MEPH.
Analyte Retention Time (min) Precursor ion (m/z) Product Ion (m/z) Collision Energy (V) Internal Standard








S-MEPH-d3 5.9 163.4 ** 148.4 19
R-MEPH-d3 4.9 163.4 ** 148.4 19
* Quantifying transition, ** dehydrated precursor ion.
4.8. Determination of the Elution Order
To determine the elution order of the enantiomers, fractions obtained from a semi-prep
chiral chromatography injection were collected and analysed by CD. Pure mephedrone
enantiomers were not commercially available at the time of this research, therefore, the
chemical analogues, R-(+)-methcathinone and S-(−)-methcathinone, were analysed by
CD alongside fractions of mephedrone. Methcathinone differs from mephedrone by the
absence of the 4-methyl group on the benzene ring (see Figure S2 in Supplementary
Materials for methcathinone structure). Since the remaining structure, including the
chemical environment surrounding the chiral centre, is identical, CD spectra of mephedrone
fractions were compared with the reference CD spectra of methcathinone enantiomers,
which have established an absolute configuration [20,21].
To isolate pure enantiomers in milligram quantities, racemic mephedrone was injected
onto a 250 × 10 mm, 5 µm Lux® Amylose-1 (Phenomenex, UK) semi-preparative column
(which provides the same selectivity as CHIRALPAK® AD-3 used for sample analysis).
The separation was performed on Agilent HPLC 1050 system (Agilent, UK) equipped
with a manual injector coupled to a diode array detector. The column was held at room
temperature and 0.1% DEA in EtOH:MeOH (20:80 v/v) was used as mobile phase in
an isocratic mode. An injection of a mephedrone solution prepared at 5 mg/mL was
performed. To check the purity of collected fractions, fractions were diluted 1 in 10 with
mobile phase and injected on the analytical CHIRALPAK® AD-3 column (150 mm × 3 mm,
3 µm). Since one enantiomer is sufficient to establish the configuration of both, only one
peak (i.e., the second eluting peak) was isolated and characterised. Pure fractions were then
dried overnight under vacuum at room temperature, dissolved in MeOH and combined.
CD spectroscopy (Photophysics Chirascan Plus spectrometer, Leatherhead, UK) was
used to analyse the combined fraction. One-millimetre Quartz Suprasil rectangular cells
(Hellma, UK) were used in the region of 450–180 nm. The instrument was flushed continu-
ously with pure evaporated nitrogen throughout the experiment. The following parameters
were employed: 2 nm spectral bandwidth, 1 nm stepsize and 1.0 s accumulation time per
point. The CD spectra were solvent baseline corrected and measured at +23 ◦C. The CD
spectra were smoothed using the Savitzky–Golay method for better presentation. Data
processing was done using APL Prodata Viewer (version 4.2.15) and spectra were modified
in Origin (version 6.0). The intensities are presented as ellipticity values (mdeg).
4.9. Pharmacokinetic Calculations
Pharmacokinetic data were determined by using a non-compartmental pharmacokinet-
ics data analysis software (PK Solutions, Summit Research Services, Colorado (version 2.0)).
Peak concentration (Cmax) and the time after dosing when it occurred (Tmax) were
observed directly from the data. The elimination rate constant (kel) was calculated using
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a log-linear regression of the elimination phase, which was achieved by plotting analyte
concentration versus time and using data points which produced r2 of at least 0.97. Elimina-
tion half-life (t1/2) was calculated as ln(2)/kel. Clearance (CL) was calculated as dose/AUC.
Volume of distribution (Vd) was calculated as CL/kel. Both CL and Vd were adjusted for
the individual’s weight and are reported here as apparent CL and Vd because absolute
bioavailability of mephedrone is unknown.
4.10. Statistical Analysis
One sample t-test and paired t-test were calculated using GraphPad Prism (version
7.0). The data set (n = 5) at each time point for the concentrations of mephedrone were
normally distributed according to the D’Agostino–Pearson normality test (p-value > 0.05).
4.11. Validation Procedure
Validation experiments determined selectivity, linearity, inter- and intra-day precision
and accuracy, limit of detection (LOD), lowest limit of quantification (LLOQ), recovery,
matrix effect and carryover. The method was validated for mephedrone according to
the Food and Drug Administration guidelines [22] and recommendations published by
Peters et al. [23]. Validation experiments are described in Supplementary Materials.
5. Conclusions
In this study, enantiomers of (±)-mephedrone were quantified in human whole blood
samples from a controlled drug administration. Mephedrone exhibited enantioselec-
tive pharmacokinetics whereas R-MEPH reached a higher Cmax, had a greater AUC and
longer t1/2.
Supplementary Materials: The following are available online at https://www.mdpi.com/1424-824
7/14/1/5/s1, Figure S1. Example calibration curves obtained for R-MEPH and S-MEPH. Table S1.
LOD, LLOQ, calibration range and calibration parameters for R-MEPH and S-MEPH in human
whole blood (NaF/KOx); Table S2. Precision and accuracy at QC Low, QC Med and QC High for
R-MEPH and S-MEPH in human whole blood (NaF/KOx); * average value of 18 measurements over
3 days; Table S3. Analyte recovery and matrix effect for R-MEPH and S-MEPH at QC Low and QC
High in human whole blood (NaF/KOx); Figure S2. Chemical structure of (±)-mephedrone and
(±)-methcathinone; Figure S3. Chromatogram showing separation of (±)-mephedrone (used for
preparation of calibration standards and quality control samples) into its enantiomers on LC-MS;
Figure S4. Chromatogram showing separation of (±)-mephedrone (used for administration) into its
enantiomers on HPLC-DAD. A superimposed chromatogram in orange shows one of the collected
fractions.
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